Prognostic Significance of New-Onset Atrial Fibrillation in Patients with Non-Hodgkin's Lymphoma Treated with Anthracyclines
Cancer therapeutics –related cardiac dysfunction induced by anthracycline is highly problematic, and its early recognition is of importance. Atrial fibrillation (AF) is sometimes seen after anthracycline chemotherapy. We aimed to test whether new-onset AF predicts anthracycline-induced heart failure. We prospectively studied 249 lymphoma patients who received anthracyclines. The patients were followed up with a frequent electrocardiographic examination. Fifteen (6%) patients newly developed AF after the chemotherapy, and during a mean follow-up of 34 months they had a higher incidence of acute heart failure (40 % vs.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Michitaka Amioka, Akinori Sairaku, Tetsuro Ochi, Takenori Okada, Hideki Asaoku, Taiichi Kyo, Yasuki Kihara Source Type: research
More News: Atrial Fibrillation | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Electrocardiogram | Heart | Heart Failure | Lymphoma | Non-Hodgkin's Lymphoma